• 1
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 1029.
  • 2
    Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. New Engl J Med 2006; 355: 254250.
  • 3
    Niault TS, Baccarini M. Targets of Raf in tumorigenesis. Carcinogenesis 2010; 31: 116574.
  • 4
    Avruch J, Zhang XF, Kyriakis JM. Raf meets Ras: completing the framework of a signal transduction pathway. Trends Bio Sci 1994; 19: 27983.
  • 5
    Casar B, Pinto A, Crespo P. Essential role of ERK dimers in the activation of cytoplasmic but not nuclear substrates by ERK-scaffold complexes. Mol Cell 2008; 31: 70821.
  • 6
    Riva C, Lavieille JP, Reyt E, Brambilla E, Lunardi J, Brambilla C. Differential c-myc, c-jun, c-raf and p53 expression in squamous cell carcinoma of the head and neck: implication in drug and radioresistance. Eur J Cancer Part B, Oral Oncol 1995; 31B: 38491.
  • 7
    Cekanova M, Majidy M, Masi T, Al-Wadei HA, Schuller HM. Overexpressed Raf-1 and phosphorylated cyclic adenosine 3′-5′-monophosphatate response element-binding protein are early markers for lung adenocarcinoma. Cancer 2007; 109: 116473.
  • 8
    Hagemann C, Gloger J, Anacker J et al. RAF expression in human astrocytic tumors. Int J Mol Med 2009; 23: 1731.
  • 9
    The Royal College of Radiologists Clinical Oncology Information Network. Guidelines on the non-surgical management of lung cancer. Clin Oncol (R Coll Radiol) 1999; 11: S153.
  • 10
    Travis WD, Branmbilla E, Muller-Hermelink HK, Harris CC. Pathology & Genetics: Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press, 2004.
  • 11
    Sobin LH, Wittekind CH. TNM Classification of Malignant Tumours, 6th edn. Hoboken, NJ: John Wiley & Sons, 2002.
  • 12
    Dhillon T, Mauri FA, Bellezza G et al. Overexpression of the mammalian target of rapamycin: a novel biomarker for poor survival in resected early stage non-small cell lung cancer. J Thorac Oncol 2010; 5: 3149.
  • 13
    Le HK, Graham L, Cha E, Morales JK, Manjili MH, Bear HD. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int Immunopharmacol 2009; 9: 9009.
  • 14
    Poleri C, Morero JL, Nieva B et al. Risk of recurrence in patients with surgically resected stage I non-small cell lung carcinoma: histopathologic and immunohistochemical analysis. Chest 2003; 123: 185867.
  • 15
    Farhat FS, Tfayli A, Fakhruddin N et al. Expression, prognostic and predictive impact of VEGF and bFGF in non-small cell lung cancer. Crit Rev Oncol Hematol 2012. doi: 10.1016/j.critrevonc.2012.02.012 [Epub ahead of print].
  • 16
    Thanopoulou E, Kotzamanis G, Pateras IS et al. The single nucleotide polymorphism g.1548A >G (K469E) of the ICAM-1 gene is associated with worse prognosis in non-small cell lung cancer. Tumour Biol 2012. doi: 10.1007/s13277-012-0393-4 [Epub ahead of print].
  • 17
    Jiang YW, Chen LA. microRNAs as tumor inhibitors, oncogenes, biomarkers for drug efficacy and outcome predictors in lung cancer (review). Mol Med Reports 2012; 5: 8904.
  • 18
    Zhang LQ, Wang J, Jiang F, Xu L, Liu FY, Yin R. Prognostic value of survivin in patients with non-small cell lung carcinoma: a systematic review with meta-analysis. PLoS One 2012; 7: e34100.
  • 19
    Huang Y, Liu D, Chen B et al. Loss of bad expression confers poor prognosis in non-small cell lung cancer. Med Oncol 2011. doi: 10.1007/s12032-011-0060-4 [Epub ahead of print].
  • 20
    Kim JS, Kim ES, Liu D et al. Prognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung cancer. Cancer 2012; 118: 245465.
  • 21
    Liu D, Huang C, Kameyama K et al. E-cadherin expression associated with differentiation and prognosis in patients with non-small cell lung cancer. Ann Thorac Surg 2001; 71: 94954; discussion 54–5.
  • 22
    Sterlacci W, Fiegl M, Tzankov A. Prognostic and predictive value of cell cycle deregulation in non-small-cell lung cancer. Pathobiology 2012; 79: 17594.
  • 23
    Kerkhoff E, Fedorov LM, Siefken R, Walter AO, Papadopoulos T, Rapp UR. Lung-targeted expression of the c-Raf-1 kinase in transgenic mice exposes a novel oncogenic character of the wild-type protein. Cell Growth Differ 2000; 11: 18590.
  • 24
    Rohrbeck A, Muller VS, Borlak J. Molecular characterization of lung dysplasia induced by c-Raf-1. PLoS One 2009; 4: e5637.
  • 25
    Udell CM, Rajakulendran T, Sicheri F, Therrien M. Mechanistic principles of RAF kinase signaling. Cell Mol Life Sci 2011; 68: 55365.